Viracta Therapeutics, Inc. (VIRX) DCF Valuation

Viracta Therapeutics, Inc. (Virx) Valoración de DCF

US | Healthcare | Biotechnology | NASDAQ
Viracta Therapeutics, Inc. (VIRX) DCF Valuation
  • ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
  • ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
  • ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
  • ✓ No Se Necesita Experiencia; Fáciles De Seguir

Viracta Therapeutics, Inc. (VIRX) Bundle

Get Full Bundle:
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

Ingementada para su precisión, nuestra calculadora DCF (VIRX) le permite evaluar la valoración de Viracta Therapeutics, Inc. utilizando datos financieros del mundo real y ofrece una flexibilidad completa para modificar todos los parámetros esenciales para las proyecciones mejoradas.


Discounted Cash Flow (DCF) - (USD MM)

Year AY1
2019		 AY2
2020		 AY3
2021		 AY4
2022		 AY5
2023		 FY1
2024		 FY2
2025		 FY3
2026		 FY4
2027		 FY5
2028
Revenue 2.1 .1 .0 .0 .0 .0 .0 .0 .0 .0
Revenue Growth, % 0 -94.21 -100 0 0 -48.55 -48.55 -48.55 -48.55 -48.55
EBITDA -22.8 -18.8 -114.1 -48.4 -46.9 .0 .0 .0 .0 .0
EBITDA, % -1100.63 -15640.83 100 100 100 20 20 20 20 20
Depreciation .0 .0 .2 .2 .5 .0 .0 .0 .0 .0
Depreciation, % 0.15123 26.67 100 100 100 65.36 65.36 65.36 65.36 65.36
EBIT -22.8 -18.8 -114.3 -48.6 -47.4 .0 .0 .0 .0 .0
EBIT, % -1100.78 -15667.5 100 100 100 20 20 20 20 20
Total Cash 34.6 47.1 103.6 91.0 53.7 .0 .0 .0 .0 .0
Total Cash, percent .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Account Receivables .0 .0 .0 .0 .3
Account Receivables, % 0 0 100 100 100
Inventories .0 .0 .0 -.9 .0 .0 .0 .0 .0 .0
Inventories, % 0 0 100 100 100 60 60 60 60 60
Accounts Payable .8 1.6 2.9 2.5 2.4 .0 .0 .0 .0 .0
Accounts Payable, % 38.16 1297.5 100 100 100 87.63 87.63 87.63 87.63 87.63
Capital Expenditure .0 -.1 -4.3 .0 -.1 .0 .0 .0 .0 .0
Capital Expenditure, % 0 -45.83 100 100 100 -9.17 -9.17 -9.17 -9.17 -9.17
Tax Rate, % 0 0 0 0 0 0 0 0 0 0
EBITAT -22.8 -19.0 -202.2 -49.2 -47.4 .0 .0 .0 .0 .0
Depreciation
Changes in Account Receivables
Changes in Inventories
Changes in Accounts Payable
Capital Expenditure
UFCF -22.0 -18.2 -204.9 -48.5 -48.3 -2.2 .0 .0 .0 .0
WACC, % 12.81 12.81 12.81 12.81 12.81 12.81 12.81 12.81 12.81 12.81
PV UFCF
SUM PV UFCF -1.9
Long Term Growth Rate, % 2.00
Free cash flow (T + 1) 0
Terminal Value 0
Present Terminal Value 0
Enterprise Value -2
Net Debt 13
Equity Value -15
Diluted Shares Outstanding, MM 39
Equity Value Per Share -0.39

What You Will Get

  • Pre-Filled Financial Model: Viracta Therapeutics' actual data enables precise DCF valuation.
  • Full Forecast Control: Adjust revenue growth, margins, WACC, and other key drivers.
  • Instant Calculations: Automatic updates ensure you see results as you make changes.
  • Investor-Ready Template: A refined Excel file designed for professional-grade valuation.
  • Customizable and Reusable: Tailored for flexibility, allowing repeated use for detailed forecasts.

Key Features

  • Comprehensive Data: Viracta Therapeutics’ historical financial statements and pre-filled projections.
  • Customizable Variables: Adjust WACC, tax rates, revenue growth, and EBITDA margins as needed.
  • Real-Time Insights: View Viracta Therapeutics’ intrinsic value update instantly.
  • Intuitive Visuals: Dashboard graphs illustrate valuation outcomes and essential metrics.
  • Engineered for Precision: A specialized tool designed for analysts, investors, and finance professionals.

How It Works

  1. Download the Template: Gain immediate access to the Excel-based VIRX DCF Calculator.
  2. Input Your Assumptions: Modify the yellow-highlighted cells for growth rates, WACC, margins, and other variables.
  3. Instant Calculations: The model automatically recalculates Viracta Therapeutics’ intrinsic value.
  4. Test Scenarios: Experiment with various assumptions to assess potential changes in valuation.
  5. Analyze and Decide: Utilize the results to inform your investment or financial analysis.

Why Choose Viracta Therapeutics Calculator?

  • Accuracy: Utilizes real Viracta Therapeutics financials for precise data.
  • Flexibility: Allows users to easily adjust and experiment with inputs.
  • Time-Saving: Eliminate the need to create a financial model from the ground up.
  • Professional-Grade: Crafted with the expertise and usability expected at the CFO level.
  • User-Friendly: Simple to navigate, even for those lacking advanced financial modeling skills.

Who Should Use This Product?

  • Biotech Students: Explore drug development processes and apply them using real-world data.
  • Researchers: Integrate cutting-edge therapeutic models into your studies or publications.
  • Investors: Evaluate your investment strategies and analyze valuation metrics for Viracta Therapeutics, Inc. (VIRX).
  • Market Analysts: Enhance your analysis with a tailored, user-friendly DCF model specific to biotech companies.
  • Healthcare Entrepreneurs: Understand how public biotech firms like Viracta Therapeutics, Inc. (VIRX) are assessed in the market.

What the Template Contains

  • Operating and Balance Sheet Data: Pre-filled Viracta Therapeutics historical data and forecasts, including revenue, EBITDA, EBIT, and capital expenditures.
  • WACC Calculation: A dedicated sheet for Weighted Average Cost of Capital (WACC), including parameters like Beta, risk-free rate, and share price.
  • DCF Valuation (Unlevered and Levered): Editable Discounted Cash Flow models showing intrinsic value with detailed calculations.
  • Financial Statements: Pre-loaded financial statements (annual and quarterly) to support analysis.
  • Key Ratios: Includes profitability, leverage, and efficiency ratios for Viracta Therapeutics, Inc. (VIRX).
  • Dashboard and Charts: Visual summary of valuation outputs and assumptions to analyze results easily.

No products were found matching.